Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 3/20 | 0.37 |
| ▸ | BUB1 | O43683 | 10/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.34 |
| ▸ | METAP2 | P50579 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3227116 | 0.85 | CDC7 (0.52) | CDC7BUB1 | |
| SCHEMBL3224009 | 0.75 | CDC7 (0.35) | CDC7BUB1METAP2 | |
| SCHEMBL3225560 | 0.67 | CDC7 (0.68) | CDC7BUB1 | |
| SCHEMBL26924400 | 0.60 | HTT (0.41) | — | |
| SCHEMBL4444514 | 0.60 | DYRK1A (0.42) | CDC7BUB1 | |
| SCHEMBL16111077 | 0.59 | HTR1A (0.39) | HTR2B | |
| SCHEMBL7489227 | 0.59 | PLK1 (0.53) | ALDH1A1 | |
| SCHEMBL5460179 | 0.58 | RIPK3 (0.60) | CDC7BUB1 | |
| SCHEMBL13859948 | 0.57 | IMPDH2 (0.50) | CDC7ALDH1A1 | |
| SCHEMBL6921111 | 0.57 | CSNK2A2 (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2120933-B1 | ISOQUINOLINOPYRROLOPYRIDINONES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2015-07-08 | — | — | EP | claimed |
| US-20100056556-A1 | ISOQUINOLINOPYRROLOPYRIDINONES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-03-04 | — | — | US | claimed |
| EP-2120933-B1 | ISOQUINOLINOPYRROLOPYRIDINONES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2015-07-08 | — | — | EP | disclosed |
| US-8293762-B2 | Isoquinolinopyrrolopyridinones active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-10-23 | — | — | US | disclosed |
| US-20100056556-A1 | ISOQUINOLINOPYRROLOPYRIDINONES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056556-A1 | ISOQUINOLINOPYRROLOPYRIDINONES ACTIVE AS KINASE INHIBITORS | CDK2, CDK1, CDK3 | CDC7 118/4885BUB1 394/4885CACNA1B 4388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.